Strategic partnership Pharmaron Biologics and CGT capabilities span discovery to market with strong CRO and CDMO offerings, presenting opportunities for co-development for biologics and gene therapies with pharma partners seeking integrated solutions.

CGT expansion Recent news highlights collaborations and investments in gene therapy and organ-on-a-chip technologies, signaling a growth trajectory in CGT manufacturing and analytical services ideal for customers scaling from preclinical to commercial stages.

Global capacity Investment in viral vector, DNA, and mRNA manufacturing facilities across Europe and the UK, plus a Liverpool CGT facility, points to potential for regional manufacturing partnerships and supply chain diversification.

Regulatory readiness Extensive regulatory support across IND and BLA filings complements development work, enabling sales conversations with sponsors needing end-to-end regulatory guidance and submission readiness.

Strategic collaborations Active partnerships with CN Bio and major pharma players indicate a favorable ecosystem for joint development programs, offering pathways to co-fund or preferential access to Pharmaron’s CGT and biologics capabilities.